Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Lori Woods bought 23,750 shares of the stock in a transaction on Thursday, November 12th. The shares were bought at an average price of $0.84 per share, for a total transaction of $19,950.00. Following the purchase, the director directly owned 28,557 shares in the company, valued at approximately $23,987.88. This trade represents a 494.07% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Perspective Therapeutics Price Performance
Shares of CATX stock opened at $0.94 on Monday. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $2.11 and a 200-day moving average price of $3.44. Perspective Therapeutics, Inc. has a 52 week low of $0.78 and a 52 week high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. On average, sell-side analysts predict that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.
Institutional Trading of Perspective Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP bought a new position in shares of Perspective Therapeutics in the first quarter worth approximately $26,424,000. Affinity Asset Advisors LLC increased its stake in shares of Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after purchasing an additional 2,864,582 shares in the last quarter. Avidity Partners Management LP raised its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the period. Spruce Street Capital LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter valued at $10,955,000. Finally, Marshall Wace LLP purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at $4,075,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on CATX shares. Royal Bank Of Canada downgraded Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $14.00 to $4.00 in a research note on Monday, October 26th. Piper Sandler dropped their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. William Blair assumed coverage on Perspective Therapeutics in a research note on Friday, September 18th. They set an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $7.00 price target (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. Finally, BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Perspective Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $10.10.
Read Our Latest Research Report on Perspective Therapeutics
About Perspective Therapeutics
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Recommended Stories
- Five stocks we like better than Perspective Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
